Skip to main
  1. Stocks
  2. Sutro Biopharma Inc
  3. Forecast
STRO

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sutro Biopharma is supported by an increasingly differentiated ADC platform, led by STRO-004’s early clinical signals of activity across PDAC, HNSCC, and NSCLC in 49 heavily pretreated patients, alongside a favorable safety/PK profile with a 6% discontinuation rate, nearly seven-day half-life, and low free exatecan exposure. The company’s pipeline breadth strengthens the long-term thesis, as STRO-006 is expected to enter Ph 1 in 3Q26 and STRO-227 is on track for an IND submission in 2026, while preclinical data suggest superior antitumor activity and feasibility for dual-payload delivery. Financially, Sutro ended 2Q26 with $164.3MM in cash, cash equivalents, and marketable securities, which management expects to fund operations into at least 2Q28, giving it runway to advance multiple programs.

Bears say

Sutro Biopharma is a high-risk clinical-stage developer whose value depends heavily on unproven ADC assets, making the investment case vulnerable to trial failure if efficacy or safety fall short in current or future studies. Its outlook is further pressured by regulatory and commercial uncertainty, since approval from the FDA and foreign agencies is not guaranteed and delays would likely impair commercialization, while dependence on partners adds another layer of execution risk. Despite being well-funded with cash, cash equivalents, and short-term investments, it may still need additional equity financing to complete development, and intense competition from larger biotechnology and pharmaceutical rivals could erode market opportunity.

STRO has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

STRO Analyst Forecast & Price Prediction

Get the latest STRO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in STRO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Buy based on their latest research and market trends.

According to 9 analysts, STRO has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


STRO Analyst Forecast & Price Prediction

Get the latest STRO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in STRO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover STRO stock data and trends